Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ: INCY )

71.93 -0.54 (-0.75%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,013,332
Open 72.87
Bid (Size) 70.48 (1)
Ask (Size) 73.31 (1)
Prev. Close 72.47
Today's Range 71.85 - 73.00
52wk Range 50.35 - 83.95
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline
Incyte plans a transformational 2025 with four potential drug launches, pivotal trial readouts, and significant pipeline milestones targeting billion-dollar markets. 
Via Benzinga
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
From Incyte
Via Business Wire

Performance

YTD
+3.45%
+3.45%
1 Month
+4.49%
+4.49%
3 Month
+10.20%
+10.20%
6 Month
+10.34%
+10.34%
1 Year
+16.96%
+16.96%

More News

Read More
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
NASDAQ:INCY, an undervalued stock with good fundamentals.
Via Chartmill
The Analyst Verdict: Incyte In The Eyes Of 15 Experts
Via Benzinga
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte Corporation (INCY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
Via ACCESSWIRE
Investors who lost money on Incyte Corporation should contact Levi & Korsinsky about an ongoing investigation - INCY
Via ACCESSWIRE
Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - INCY
Via ACCESSWIRE
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
Via The Motley Fool
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
From Incyte
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Incyte Announces Updated Presentation Time for Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
From Incyte
Via Business Wire
Target, Alibaba And Temu Parent PDD Are Among Top 10 Large-Cap Losers Last Week (Nov 18-Nov 22): Are The Others In Your Portfolio?
Via Benzinga
Stock Market Rallies After Key Test; Nvidia, Target, Google, Bitcoin In Focus: Weekly Review
Via Investor's Business Daily
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued.
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Nasdaq Reverses Losses Amid Nvidia Fanfare
Via Talk Markets
Gold Moves Higher; Medtronic Posts Upbeat Results
Via Benzinga
Stocks Move Higher, Walmart Hits Record High, Natural Gas Reaches 5-Month Peak: What's Driving Markets Tuesday?
Via Benzinga
Topics Energy
Exposures Fossil Fuels
What's Going On With Incyte Shares Tuesday?
Via Benzinga
Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.